Skip to main content

Nikole Hannah-Jones

Monday, November 29, 2021
7:30pm Pacific Time
Venue: Sydney Goldstein Theater
Journalist Nikole Hannah-Jones has spent her career investigating racial inequality and injustice. She is the Pulitzer Prize-winning creator of the 1619 Project and a staff writer at The New York Times Magazine. In 2016, Hannah-Jones co-founded the Ida B. Wells Society for Investigative Reporting, which seeks to increase the number of reporters and editors of color. 
 
In late August 1619, a ship arrived in the British colony of Virginia bearing a cargo of twenty to thirty enslaved people from Africa. Their arrival led to the barbaric and unprecedented system of American chattel slavery that would last for the next 250 years. This is sometimes referred to as the country’s original sin, but it is more than that: it is the source of so much that still defines the United States. The New York Times Magazine’s “1619 Project” issue reframed our understanding of American history by placing slavery and its continuing legacy at the center of our national narrative. This new book, The 1619 Project: A New Origin Story, substantially expands on that work, weaving together eighteen essays that explore the legacy of slavery in present-day America with thirty-six poems and works of fiction that illuminate key moments of oppression, struggle, and resistance. The essays show how the inheritance of 1619 reaches into every part of contemporary American society, from politics, music, diet, traffic, and citizenship to capitalism, religion, and our democracy itself. Contributors include Michelle Alexander, Sonia Sanchez, Reginald Dwayne Betts, Barry Jenkins, Yaa Gyasi, Ibram X. Kendi, Claudia Rankine, Bryan Stevenson, Jesmyn Ward, Lynn Nottage, Danez Smith, Yusef Komunyakaa, and many more.

 

A limited number of tickets include signed copies of The 1619 Project: A New Origin Story.

 

You and your guests must be fully vaccinated to attend this event; proof of vaccination is required upon arrival. Full vaccination is defined as completion of the two-dose regimen of Pfizer or Moderna vaccines or one dose of Johnson & Johnson vaccine administered two weeks or more in advance of the event.